View Financial HealthCardiac Biotech Solutions 배당 및 자사주 매입배당 기준 점검 0/6Cardiac Biotech Solutions 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Sep 26Cardiac Biotech Solutions, Inc. Secures Health Canada License for MyCardia AT Device, Now Branded as CardioHolter ATCardiac Biotech Solutions Inc. announced that its MyCardia AT device has been issued a Medical Device License (MDL) by Health Canada and is now approved for import into Canada, effective immediately. The device, rebranded as the CardioHolter AT, will be tested and distributed through CBSC's manufacturing partner, Nasiff Associates, located in Central Square, NY. Nasiff Associates is a Health Canada-licensed establishment operating under a certified ISO 13485 Quality Management System (QMS) that complies with Health Canada standards for Class II medical devices. CBSC's exclusive Canadian distributor, Your Heart Protector Corp. (Calgary, Alberta), has placed an initial order for CardioHolter AT devices totaling $375,000 USD. Delivery of the first 1,000 devices will occur upon completion of production (currently underway), with the balance scheduled for shipment within 90-120 days. In addition to revenue from device sales, CBSC has implemented a monthly rental program that provides recurring income whenever devices are deployed in hospitals and healthcare facilities. The program fees include access to the device, the AWS Cloud-based monitoring platform, and patient-facing mobile applications. Whether using standard landline telephone connections or newer cellular and WiFi-enabled technologies, patients can reliably transmit recorded ECG data to their physicians for timely review and diagnosis. This technology empowers physicians to achieve better patient outcomes, improved diagnoses, and enhanced quality of life regardless of a patient's location. The Company continues to advance the global commercialization of its MyCardia AT cardiac event monitoring platform, which integrates lightweight, easy-to-use wearable technology with AWS Cloud-based connectivity and mobile applications for iOS, Android, and WeChat. With regulatory clearance already secured in the United States and Canada, and an additional submission progressing in China, CBSC's mission is to deliver cardiac monitoring solutions worldwide.공시 • Oct 03CB Scientific, Inc. Announces Chief Financial Officer ChangesCB Scientific, Inc. announced that the Company's Board of Directors appointed Mr. William "Trip" Thomas as its Chief Financial Officer effective October 1, 2024. Mr. Thomas is replacing Ms. Brooke Turk who formally tendered her resignation effective September 30, 2024. Ms. Turk's resignation was not the result of any disagreement or conflict with the Company. Mr. Thomas earned a Bachelor of Science degree in Accounting from the University of Tampa and holds a Bachelor of Science degree in Agribusiness from the University of Florida. He is a licensed Certified Public Account in the State of Florida.공시 • Sep 07CB Scientific, Inc. Announces FDA 510(k) Submission of Enhanced myCam Cardiac Event MonitorCB Scientific, Inc. announced that it has completed the regulatory testing phase of its latest myCam cardiac event monitor design and has formally tendered a 510(k) submission for Clearance to Market to the U.S. Food and Drug Administration (FDA). The company anticipates a response from the FDA for this 510(k) submission in approximately 90 to 120 days. During the review process, CBSC looks forward to collaborating with the FDA in a concerted effort to obtain Clearance to Market for the new myCam product as quickly as possible. Upon receiving FDA clearance, the company intends to market the device domestically, as well as internationally throughout Asia, Latin America, India and the Middle East, each of which require FDA certification.공시 • Mar 05CB Scientific, Inc. Announces Appointment of Jeslie Chui as New Director for Asia PacificCB Scientific. Inc. announced the appointment of Jeslie Chui as Director of Business Development Asia Pacific for CB Scientific Inc. effective March 1, 2021. In this position Mr. Chui will work to increase company recognition and awareness of CBSC and its subsidiary My-Cardia, identify and develop corporate strategies for expansion and the associated marketing platforms to support these strategies, and assist in corporate fundraising in the region. Through his various entrepreneurial roles in Hong Kong and China, Jeslie Chui has been instrumental in raising venture capital including financial advisory and business development for companies from a wide variety of industries throughout his career. For more than twenty years, Mr. Chui has been a renowned veteran financial market professional in the Asia Pacific region. His considerable knowledge and extensive work experience include new business development, IPO advisory, Deal structuring, private equity funding, and merger and acquisitions. Strategic management planning, product development, information system implementation and management, and legal compliance are other areas of his expertise. Throughout his career Jeslie has held positions with Mithera Capital, a US based Private Equity, as their Chief Marketing Officer and Head of Asia Pacific market; Chief Strategic Officer for Zhong Tai International Financial Holdings Ltd.; and Head of Wealth Management for China Galaxy International (a subsidiary of China Galaxy Securities) to name a few. In addition to his new role with CBSC, Mr. Chui also serves as the Head of Corporate Advisory Services for CCTH, a founding member of AG China. He has earned several academic degrees including a Master of Engineering in Electronic Commerce from The University of Hong Kong; Executive Master of Business Administration from The Chinese University of Hong Kong; Master of Science in Investment Management from The Hong Kong University of Science and Technology; Master of Law (LLM) in Chinese Business Law from The Chinese University of Hong Kong; and Master of Corporate Governance with Distinction from the Hong Kong Polytechnic University. Jeslie Chui is also an Adjunct Professor for the College of Business at the City University of Hong Kong and an Honorary Professor at Huashang College for the Guangdong University of Finance and Economics and has authored 24 books on investment products and corporate finance.공시 • Feb 24CB Scientific, Inc. (OTCPK:CBSC) has signed a definitive agreement to acquire Cardiolink Corporation.CB Scientific, Inc. (OTCPK:CBSC) has signed a definitive agreement to acquire Cardiolink Corporation on February 23, 2021. The deal is expected to close by May 2021.공시 • Dec 30CB Scientific. Inc. Announces Addition of Dozens of New Device Clinical Trials of my-Cam Device and New Hospital Monitoring Contracts Through Mango Wellness Co., Ltd. and My Cardia Thailand Co., LtdCB Scientific. Inc. announced the addition of dozens of new device clinical trials of its my-Cam device and new hospital monitoring contracts through the Company’s authorized distributor, Mango Wellness Co. Ltd. (MWC) and My Cardia Thailand Co. Ltd. (MCT) in Thailand. Mango Wellness Co. Ltd.’s successful participation as an exhibitor at the Royal College of Physicians of Thailand Annual Conference in Pattaya, Thailand, Oct. 29-31, and again at the Thailand Cardiologist Annual Conference in Hua Hin, Thailand, Dec. 10-12, produced overwhelming interest from more than 160 physicians who have requested on-site evaluations of the Company’s my-Cam monitor and my-Cardia software portal in these two regions of Thailand. Mango Wellness Co. Ltd. and My Cardia Thailand anticipate adding 100 contracted hospitals in the first quarter of 2021, totaling more than 1,000 ambulatory remote cardiac event monitoring tests during this time.공시 • Oct 10CB Scientific, Inc. Announces the Launch of My-Cardia ECG Products and Services in ThailandCB Scientific. Inc. announces the targeted start of cardiac lab services operations in the country of Thailand through the Company’s exclusive authorized distributor, Mango Wellness Co., Ltd. (MWC) and My Cardia Thailand Co., Ltd. (MCT), beginning Oct. 29, 2020. Under terms of the distribution agreement, Mango Wellness Co., Ltd. and My Cardia Thailand Co., Ltd. will be the exclusive distributor for CBSC’s proprietary FDA and CE-cleared EKG my-Cam Cardiac Event Monitor, the interactive cloud-based My-Cardia acquisition software, and the associated smartphone apps for both iOS and Android platforms in Thailand. The My-Cardia product line is designed specifically for the Remote Cardiac Ambulatory ECG market to help in the detection of abnormal heart rhythms while providing improved compliance for the patient, as well as more timely, convenient and accurate information for the physician. The distribution agreement may be expanded with additional products and territories in the future. Financial terms of the agreement were not disclosed. CB Scientific plans to make further announcements to keep its shareholders, industry participants and the public markets informed through press releases and regulatory filings as new developments occur.공시 • Sep 24CB Scientific, Inc. (OTCPK:CBSC) acquired Operating Business Assets of Prevent Health Care International Corp. from Prevent Health Care International Corp.CB Scientific, Inc. (OTCPK:CBSC) acquired Operating Business Assets of Prevent Health Care International Corp. from Prevent Health Care International Corp. on September 22, 2020. CB Scientific, Inc. (OTCPK:CBSC) completed the acquisition of Operating Business Assets of Prevent Health Care International Corp. from Prevent Health Care International Corp. on September 22, 2020.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 CBSC 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: CBSC 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Cardiac Biotech Solutions 배당 수익률 vs 시장CBSC의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (CBSC)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Pharmaceuticals)2.0%분석가 예측 (CBSC) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 CBSC 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 CBSC 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 CBSC 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: CBSC 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/18 01:57종가2026/06/18 00:00수익2018/12/31연간 수익2018/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cardiac Biotech Solutions Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Sep 26Cardiac Biotech Solutions, Inc. Secures Health Canada License for MyCardia AT Device, Now Branded as CardioHolter ATCardiac Biotech Solutions Inc. announced that its MyCardia AT device has been issued a Medical Device License (MDL) by Health Canada and is now approved for import into Canada, effective immediately. The device, rebranded as the CardioHolter AT, will be tested and distributed through CBSC's manufacturing partner, Nasiff Associates, located in Central Square, NY. Nasiff Associates is a Health Canada-licensed establishment operating under a certified ISO 13485 Quality Management System (QMS) that complies with Health Canada standards for Class II medical devices. CBSC's exclusive Canadian distributor, Your Heart Protector Corp. (Calgary, Alberta), has placed an initial order for CardioHolter AT devices totaling $375,000 USD. Delivery of the first 1,000 devices will occur upon completion of production (currently underway), with the balance scheduled for shipment within 90-120 days. In addition to revenue from device sales, CBSC has implemented a monthly rental program that provides recurring income whenever devices are deployed in hospitals and healthcare facilities. The program fees include access to the device, the AWS Cloud-based monitoring platform, and patient-facing mobile applications. Whether using standard landline telephone connections or newer cellular and WiFi-enabled technologies, patients can reliably transmit recorded ECG data to their physicians for timely review and diagnosis. This technology empowers physicians to achieve better patient outcomes, improved diagnoses, and enhanced quality of life regardless of a patient's location. The Company continues to advance the global commercialization of its MyCardia AT cardiac event monitoring platform, which integrates lightweight, easy-to-use wearable technology with AWS Cloud-based connectivity and mobile applications for iOS, Android, and WeChat. With regulatory clearance already secured in the United States and Canada, and an additional submission progressing in China, CBSC's mission is to deliver cardiac monitoring solutions worldwide.
공시 • Oct 03CB Scientific, Inc. Announces Chief Financial Officer ChangesCB Scientific, Inc. announced that the Company's Board of Directors appointed Mr. William "Trip" Thomas as its Chief Financial Officer effective October 1, 2024. Mr. Thomas is replacing Ms. Brooke Turk who formally tendered her resignation effective September 30, 2024. Ms. Turk's resignation was not the result of any disagreement or conflict with the Company. Mr. Thomas earned a Bachelor of Science degree in Accounting from the University of Tampa and holds a Bachelor of Science degree in Agribusiness from the University of Florida. He is a licensed Certified Public Account in the State of Florida.
공시 • Sep 07CB Scientific, Inc. Announces FDA 510(k) Submission of Enhanced myCam Cardiac Event MonitorCB Scientific, Inc. announced that it has completed the regulatory testing phase of its latest myCam cardiac event monitor design and has formally tendered a 510(k) submission for Clearance to Market to the U.S. Food and Drug Administration (FDA). The company anticipates a response from the FDA for this 510(k) submission in approximately 90 to 120 days. During the review process, CBSC looks forward to collaborating with the FDA in a concerted effort to obtain Clearance to Market for the new myCam product as quickly as possible. Upon receiving FDA clearance, the company intends to market the device domestically, as well as internationally throughout Asia, Latin America, India and the Middle East, each of which require FDA certification.
공시 • Mar 05CB Scientific, Inc. Announces Appointment of Jeslie Chui as New Director for Asia PacificCB Scientific. Inc. announced the appointment of Jeslie Chui as Director of Business Development Asia Pacific for CB Scientific Inc. effective March 1, 2021. In this position Mr. Chui will work to increase company recognition and awareness of CBSC and its subsidiary My-Cardia, identify and develop corporate strategies for expansion and the associated marketing platforms to support these strategies, and assist in corporate fundraising in the region. Through his various entrepreneurial roles in Hong Kong and China, Jeslie Chui has been instrumental in raising venture capital including financial advisory and business development for companies from a wide variety of industries throughout his career. For more than twenty years, Mr. Chui has been a renowned veteran financial market professional in the Asia Pacific region. His considerable knowledge and extensive work experience include new business development, IPO advisory, Deal structuring, private equity funding, and merger and acquisitions. Strategic management planning, product development, information system implementation and management, and legal compliance are other areas of his expertise. Throughout his career Jeslie has held positions with Mithera Capital, a US based Private Equity, as their Chief Marketing Officer and Head of Asia Pacific market; Chief Strategic Officer for Zhong Tai International Financial Holdings Ltd.; and Head of Wealth Management for China Galaxy International (a subsidiary of China Galaxy Securities) to name a few. In addition to his new role with CBSC, Mr. Chui also serves as the Head of Corporate Advisory Services for CCTH, a founding member of AG China. He has earned several academic degrees including a Master of Engineering in Electronic Commerce from The University of Hong Kong; Executive Master of Business Administration from The Chinese University of Hong Kong; Master of Science in Investment Management from The Hong Kong University of Science and Technology; Master of Law (LLM) in Chinese Business Law from The Chinese University of Hong Kong; and Master of Corporate Governance with Distinction from the Hong Kong Polytechnic University. Jeslie Chui is also an Adjunct Professor for the College of Business at the City University of Hong Kong and an Honorary Professor at Huashang College for the Guangdong University of Finance and Economics and has authored 24 books on investment products and corporate finance.
공시 • Feb 24CB Scientific, Inc. (OTCPK:CBSC) has signed a definitive agreement to acquire Cardiolink Corporation.CB Scientific, Inc. (OTCPK:CBSC) has signed a definitive agreement to acquire Cardiolink Corporation on February 23, 2021. The deal is expected to close by May 2021.
공시 • Dec 30CB Scientific. Inc. Announces Addition of Dozens of New Device Clinical Trials of my-Cam Device and New Hospital Monitoring Contracts Through Mango Wellness Co., Ltd. and My Cardia Thailand Co., LtdCB Scientific. Inc. announced the addition of dozens of new device clinical trials of its my-Cam device and new hospital monitoring contracts through the Company’s authorized distributor, Mango Wellness Co. Ltd. (MWC) and My Cardia Thailand Co. Ltd. (MCT) in Thailand. Mango Wellness Co. Ltd.’s successful participation as an exhibitor at the Royal College of Physicians of Thailand Annual Conference in Pattaya, Thailand, Oct. 29-31, and again at the Thailand Cardiologist Annual Conference in Hua Hin, Thailand, Dec. 10-12, produced overwhelming interest from more than 160 physicians who have requested on-site evaluations of the Company’s my-Cam monitor and my-Cardia software portal in these two regions of Thailand. Mango Wellness Co. Ltd. and My Cardia Thailand anticipate adding 100 contracted hospitals in the first quarter of 2021, totaling more than 1,000 ambulatory remote cardiac event monitoring tests during this time.
공시 • Oct 10CB Scientific, Inc. Announces the Launch of My-Cardia ECG Products and Services in ThailandCB Scientific. Inc. announces the targeted start of cardiac lab services operations in the country of Thailand through the Company’s exclusive authorized distributor, Mango Wellness Co., Ltd. (MWC) and My Cardia Thailand Co., Ltd. (MCT), beginning Oct. 29, 2020. Under terms of the distribution agreement, Mango Wellness Co., Ltd. and My Cardia Thailand Co., Ltd. will be the exclusive distributor for CBSC’s proprietary FDA and CE-cleared EKG my-Cam Cardiac Event Monitor, the interactive cloud-based My-Cardia acquisition software, and the associated smartphone apps for both iOS and Android platforms in Thailand. The My-Cardia product line is designed specifically for the Remote Cardiac Ambulatory ECG market to help in the detection of abnormal heart rhythms while providing improved compliance for the patient, as well as more timely, convenient and accurate information for the physician. The distribution agreement may be expanded with additional products and territories in the future. Financial terms of the agreement were not disclosed. CB Scientific plans to make further announcements to keep its shareholders, industry participants and the public markets informed through press releases and regulatory filings as new developments occur.
공시 • Sep 24CB Scientific, Inc. (OTCPK:CBSC) acquired Operating Business Assets of Prevent Health Care International Corp. from Prevent Health Care International Corp.CB Scientific, Inc. (OTCPK:CBSC) acquired Operating Business Assets of Prevent Health Care International Corp. from Prevent Health Care International Corp. on September 22, 2020. CB Scientific, Inc. (OTCPK:CBSC) completed the acquisition of Operating Business Assets of Prevent Health Care International Corp. from Prevent Health Care International Corp. on September 22, 2020.